As Axogen Inc (NASDAQ:AXGN) Price Rose by $11.31 Million, Next Century Growth Investors Llc Trimmed Its Position

May 17, 2018 - By Frank Plummer

AxoGen, Inc. (NASDAQ:AXGN) Corporate Logo

Next Century Growth Investors Llc decreased its holdings by 47.07% in Axogen Inc (NASDAQ:AXGN), according to 2018Q1 Securities and Exchange filling. The company’s stock Popped Up 43.24% while Next Century Growth Investors Llc sold 314,239 shares. The health care company announced $12.90M value for the 2018Q1. Now the institutional investor is holding 353,403 shares, compared to the 667,642 from the previous quarter. For a total of shares it increased its holding in by shares in the quarter, and has risen its stake in .

Next Century Growth Investors Llc is a Minnesota-based institutional investor with more than $3.86 billion AUM in March, 2014. Taken from Next Century Growth Investors latest Adv, the fund reported to have 10 full and part-time employees. Among which 6 performing investment advisory and research functions. The institutional investor had between 26-100 clients.

AxoGen, Inc. (NASDAQ:AXGN) Ratings Coverage

In total 7 analysts cover AxoGen (NASDAQ:AXGN). “Buy” rating has 7, “Sell” are 0, while 0 are “Hold”. (NASDAQ:AXGN) has 100% bullish analysts. 11 are the (NASDAQ:AXGN)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. On Friday, March 2 the rating was maintained by Lake Street with “Buy”. On Tuesday, May 1 Cantor Fitzgerald maintained the shares of AXGN in report with “Overweight” rating. On Monday, January 8 Cantor Fitzgerald maintained the shares of AXGN in report with “Buy” rating. The company rating was maintained by Wedbush on Tuesday, November 21. The stock rating was maintained by JMP Securities with “Market Outperform” on Thursday, March 1. On Tuesday, May 1 the rating was maintained by JMP Securities with “Market Outperform”. In Tuesday, November 21 report Leerink Swann maintained it with “Outperform” rating and $30 target. On Wednesday, February 28 the firm earned “Buy” rating by Cantor Fitzgerald.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries.The firm is worth $1.66 billion. The companyÂ’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.Last it reported negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

AxoGen, Inc. (NASDAQ:AXGN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.